Pleural Mesothelioma (PM) – the status of systemic therapy

Mesothelioma is a universally lethal malignancy of serosal membranes, which commonly affects the pleura of the lung, and less commonly the peritoneum, pericardium and testes.[1] Since the first reported case of mesothelioma in 1908, where the patient survived for 8 months after diagnosis,[2] the prognosis of mesothelioma has largely remained poor. The median overall survival rates reported in population-based registry studies range between 8 to 12 months,[1] and between 12 to 18 months in contemporary clinical trials.
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Source Type: research